Streck introduces CD-Chex CD117, a flow cytometry control for CD117 that eliminates the need for laboratories to hold and validate patient samples for use as a control for CD117. The control is designed to represent abnormal peripheral blood leukocytes similar to a hematolymphoid neoplastic patient sample. The product possesses surface CD117 that is detectable with fluorescent monoclonal antibodies by flow cytometry. The CD117 positive abnormal leukocytes are distinguishable from normal leukocytes on the basis of light scatter properties, a low level of CD45 expression, and heterogeneous CD117 expression. CD-Chex CD117 features 30-day open vial stability and 90-day closed vial stability.